In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency ...

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the ...

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB – Research Report), with a price ...

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi. In the latest development, the European Commission has ...

Similar concerns have also been raised with rival anti-amyloid drug Leqembi (lecanemab) from Eisai/Biogen and have blocked its approval in the EU and Australia, as well as reimbursement approval ...

David Doane of Bucksport has been a vocal advocate for legislation and research for amyotrophic lateral sclerosis, commonly ...

The Global Cell And Gene Therapy Market is valued at USD 20.5 Billion in 2024 and is projected to reach a value of USD 128.8 ...